title: The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.
abstract: It is now well established that the efficacy of allogeneic hematopoietic stem cell transplant for eradicating a variety of hematologic malignancies is related to antitumor activity mediated by donor immune cells contained in the stem cell graft. Recent studies have provided fundamental insights into the nature of the effector cells and target molecules that are responsible for the graft versus tumor effect. T cells specific for minor histocompatibility antigens can mediate potent antitumor activity but are also responsible for graft versus host disease (GVHD). The molecular characterization of minor antigens has suggested ways of potentially separating antitumor activity from GVHD. The challenge for the future is to continue to build on our understanding of the allogeneic graft versus tumor effect and develop strategies that can be incorporated into clinical practice to augment this effect without GVHD.
authors.affiliation: D3-100, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., Seattle, WA 98109, USA. sriddell@fhcrc.org
authors.forename: Stanley R
authors.initials: SR
authors.lastname: Riddell
authors.forename: Carolina
authors.initials: C
authors.lastname: Berger
authors.forename: Makoto
authors.initials: M
authors.lastname: Murata
authors.forename: Sophia
authors.initials: S
authors.lastname: Randolph
authors.forename: Edus H
authors.initials: EH
authors.lastname: Warren
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D020544:Graft vs Leukemia Effect / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015778:Minor Histocompatibility Antigens / Q000276:immunology; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous
chemical_list: D015778:Minor Histocompatibility Antigens